Intouch Appoints SVP With Opening of Boston Office
Intouch Solutions has expanded its client base and is opening a second East Coast office in downtown Boston where industry veteran, Ann Cave, will be taking the lead. Cave will be responsible for building and managing the Boston office with a focus on supporting key client partners. She will draw upon 20 years of experience leading business strategy and marketing for building successful brands and markets in the rare disease, medical device, diagnostics, and life science industries. Cave was previously head of client services and business development for Cambridge BioMarketing, where she was responsible for guiding the growth and success of many strategic client partnerships.
“I am looking forward to growing our team in Boston, fueled by a commitment to consistently do more for our clients, the audiences they want to connect with, and for each other,” says Cave. “This is an agency filled with innovators across every discipline of our business, and I’m excited to work with such a talented and diverse team to deliver intelligent, more personalized healthcare conversations.”
Healthline Media Taps Superstar Brander
Kira Wampler joins the health information media company as a member of its Board of Directors. With her expertise in product experience, marketing, and brand strategy, Wampler is expected to help the fast-growing consumer health information site expand its market leadership. “Kira adds valuable dimension to our board with her strong consumer background and her deep brand-building and product experience,” said David Kopp, Chief Executive Officer of Healthline Media, Inc. “Our two newest board members have brought both consumer marketing and product experience with the holistic operating experience of a CEO, which has strengthened our quality-driven, profitable business and will enable us to help more people live stronger, healthier lives.”
Wampler previously served as CEO of Art.com before completing its sale to Walmart. She is well known for her Chief Marketing Officer positions at Lyft and at Trulia. She positioned Lyft as a leader in the ride sharing economy with the launch of their first-ever national marketing campaign.
The pharma company taps former Celgene CEO and Chairman, Bob Hugin, to lead a new deal-focused committee comprised of current board members in a move to satisfy wary investors. The company claims that executive veteran Hugin will lead the Board of Directors in providing oversight on mergers, acquisitions, divestitures, and other transactions.
The healthcare communications agency promotes industry veterans, Kristin Morris and Dawn Hastings, to VP, Creative Director, expanding their responsibilities and strategic oversight. Morris and Hastings were chosen to take up leadership during restructuring of the creative department within Dudnyk, where two new groups have formed to focus on insights, strategy, and ideation, as well as execution, engagement, and multichannel pull-through. The VP, Creative Directors will be expected to help the company discover more innovative, efficient ways to deliver on the evolving needs of clients as it continues to ensure its rapidly growing client base receives the best creative work in the industry.
The small-molecule development company taps former Genentech SVP of Global Product Strategy, Frank D. Lee, to take the role of Chief Executive Officer. Lee will use his extensive commercialization experience across therapy areas to help advance FORMA’s early-stage clinical pipeline closer to approvals and commercialization.
Former Pfizer clinical rare disease lead, Willem H. Scheele, MD, joins the sickle cell disease-focused biotech as its new Chief Medical Officer. He will now oversee the clinical program for their experimental med IMR-687, as well as manage the strategy, direction, and execution of Imara’s overall clinical drug development efforts. Dr. Scheele is expected to be a tremendous asset due to his lengthy experience with leading rigorous clinical development for rare diseases like Gaucher disease and transthyretin amyloid cardiomyopathy at giant pharmaceutical companies.
Having received a two-year extension on its $450 million research pact with Merck, NGM Bio appoints Hsiao D. Lieu, MD, as its new Senior Vice President, Chief Medical Officer. Previously, Dr. Lieu served as Genentech’s VP of Early Clinical Development. Now, he is trusted to help oversee clinical development of NGM Bio’s lead, mid-stage NASH experimental, NGM282.
The computational specialty biotech adds two new drug discovery and development experts to their scientific leadership team. Alan Collis, PhD, a part-time scientist at Nimbus since 2018, will transition to a full-time Vice President of Preclinical Development position. Dr. Collis has 30 years of experience in discovery chemistry, candidate selection, and development. He built an expert reputation in his former role as FORMA Therapeutics’ Executive Director of DMPK and as Novartis’ Executive Director of Scientific and Strategic Planning. Jennifer Rocnik, PhD, has been promoted to Vice President, Biology, from Director of Oncology Biology, a role she’s held since 2015. Dr. Rocnik boasts more than 12 years experience in biotech and pharma drug discovery and leads programs from target identification to development candidate nomination. Prior to joining Nimbus, she held various leadership roles in Sanofi’s oncology division.
Clinical Network Services (CNS) USA, an integrated services group focused on clinical product development, announces the appointment of Dr. Robert Malone as Principal Consultant in its Washington D.C. office. Dr. Malone brings more than 20 years of leadership experience in regulatory and medical strategy for global clinical product development. He is trusted to guide the company in adding value to clients’ early-phase programs and their U.S. regulatory strategies
The clinical-stage biotech focused on bioengineering blood cells into a new class of medicine, names Natalie Holles as a member of the Board and Greg Whitehead as Senior Vice President and Chief Quality Officer. Holles is currently President and Chief Operating Officer of Audentes Therapeutics and will use her experience in company-building, corporate development, and strategic planning to help guide the Rubius Board. Whitehead brings more than 25 years of quality-related experience to Rubius. He joins the company from bluebird bio, Inc., where he served as Vice President, Quality.
The company bringing remote surgical robots to market appoints Michele Marzola as Chairman of the Board to help oversee the general strategy and direction of the company. Marzola is a veteran investor with experience in facilitating more than 20 startup companies in the life sciences, digital, and professional services industries.